
Azenta (AZTA) Stock Forecast & Price Target
Azenta (AZTA) Analyst Ratings
Bulls say
Azenta Inc has demonstrated strong financial performance, highlighted by an adjusted EBITDA margin of 10.2%, which reflects a significant year-over-year increase of 560 basis points and exceeds consensus expectations. The company's adjusted gross margin of 47.6%, up 270 basis points year-over-year, indicates improved profitability driven by operational efficiencies and a favorable product mix. Additionally, positive growth in the Multiomics and Sample Management Solutions segments supports a bullish outlook for future revenue expansion and margin improvement.
Bears say
Azenta Inc. has provided FY25 guidance indicating lower growth expectations for both its Sample Management Solutions (SMS) and Multiomics segments, excluding B Medical from the forecast. Recent financial performance highlights a decline in revenue to $170 million, reflecting a 2% year-over-year decrease in constant currency organic growth, significantly down from the previous quarter's 25% growth rate, along with a notable 11% decline in the Sanger segment year-over-year. Increased competition in Multiomics and slower traction in SMS suggest potential for margin contraction and a risk of slowing or negative earnings per share (EPS) growth, contributing to a negative outlook for the company's financial future.
This aggregate rating is based on analysts' research of Azenta and is not a guaranteed prediction by Public.com or investment advice.
Azenta (AZTA) Analyst Forecast & Price Prediction
Start investing in Azenta (AZTA)
Order type
Buy in
Order amount
Est. shares
0 shares